Skip to Main Content

Cue Biopharma, Inc.

CUE Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
CUE Income Statement
CUE Balance Sheet
CUE Cash Flow

Recent trades of CUE by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CUE Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CUE Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CUE Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by CUE's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof Jul. 09, 2024
  • Patent Title: T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof Jun. 11, 2024
  • Patent Title: Methods for modulating an immune response May. 28, 2024
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof May. 21, 2024
  • Patent Title: Methods for modulating an immune response Apr. 16, 2024
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 20, 2024
  • Patent Title: Multimeric t-cell modulatory polypeptides and methods of use thereof Jan. 23, 2024
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 26, 2023
  • Patent Title: Methods for modulating an immune response Sep. 26, 2023
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 29, 2023
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 25, 2023
  • Patent Title: T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides Jul. 18, 2023
  • Patent Title: Tgf-β polypeptides Jul. 04, 2023
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Dec. 20, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Nov. 22, 2022
  • Patent Title: Methods for modulating an immune response Oct. 25, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Aug. 02, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jul. 05, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Jun. 28, 2022
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Sep. 14, 2021
  • Patent Title: Methods for modulating an immune response Aug. 31, 2021
  • Patent Title: Methods for modulating an immune response Feb. 23, 2021
  • Patent Title: T-cell modulatory multimeric polypeptides and methods of use thereof Feb. 23, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CUE in WallStreetBets Daily Discussion

CUE News

Recent insights relating to CUE

CNBC Recommendations

Recent picks made for CUE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CUE

CUE Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CUE Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top